Ipamorelin in Humans: Pharmacology, Phase 2 & Evidence Limits

Short answer

Ipamorelin has human evidence, and it is not a mature clinical body. Gobburu and colleagues modeled pharmacokinetics and GH response in healthy male volunteers. Beck and colleagues published a Phase 2 postoperative-ileus trial: 117 people were enrolled and 114 entered safety and the modified intention-to-treat analysis; the key efficacy endpoint — time to tolerance of a standardized solid meal — did not reach a statistically significant difference.

There is a second Phase 2 registry, NCT01280344, Completed, with 320 participants and a study-completion date of May 2014. In the sources reviewed as of September 1, 2026, we did not identify posted results on ClinicalTrials.gov for that record. A completed registry is not a numerical efficacy paper.^2,3,5

Raun and colleagues, 1998, are not a human trial. They are preclinical pharmacology in rat pituitary cells, rats, and swine. That source is not used here to claim that Ipamorelin does not raise cortisol in people, that it has no adverse effects, or that it is generally safer.¹

This page inventories the component. It does not turn GH into muscle, fat, sleep, recovery, anti-aging, or performance. It does not offer a technique or a regimen. The map is in the CJC-1295 + Ipamorelin hub.

Raun 1998

Raun, Hansen, Johansen, and colleagues published in European Journal of Endocrinology. The work characterizes the peptide in animal and cell models. It can explain why the molecule was developed and why selectivity versus other secretagogues was discussed in those systems.¹

A preclinical model does not demonstrate an absence of cortisol effects in people. It does not demonstrate that Ipamorelin “has no adverse effects.” It does not demonstrate greater safety versus another secretagogue in human use. If a selectivity sentence is cited, it is cited with the model: rat, swine, pituitary cell.¹

This paper also does not administer CJC-1295. It is not combination evidence. It is included because much secondary literature treats it as if it were already a human safety fact; here it stays in its class: preclinical work on the component.

Gobburu 1999

Gobburu, Agersø, Jusko, and Ynddal published in Pharmaceutical Research. The design is a modeling study in healthy people. It shows that Ipamorelin, under those conditions, can be related to a GH response. That is human pharmacology of the component.²

Forty designed exposures — five levels, eight people each — are not an efficacy program. There is no ileus endpoint here, no growth-hormone-deficiency endpoint, and no body-composition endpoint. Infusion quantities, if they appear in the source, stay in the source; they are not turned into instructions.²

A GH response in volunteers does not prove that Ipamorelin works for a gastrointestinal endpoint. It also does not prove the opposite. Those are different questions, with different trials. The false bridge — “it releases GH, therefore it works for X” — is the error this page avoids.²

Beck 2014

Beck, Sweeney, McCarter, and the Ipamorelin 201 Study Group published in the International Journal of Colorectal Disease. The companion registry is NCT00672074, Completed; registry completion is not independent efficacy evidence beyond the paper.^3,4

The number that cannot be hidden is the key endpoint. Time to a standardized solid meal was not statistically significant. A Phase 2 trial that misses its primary outcome is not summarized as a clinical success, as “almost worked,” or as proof that the molecule lacks activity on another axis.³

The setting is postoperative gastric motility, not the blend with CJC-1295, not body composition, and not a growth-hormone-deficiency use. The route and the trial environment are those of the ileus clinical-development program. They are not generalized here to every route or to a research vial.³

The failed gastrointestinal endpoint is also not used to claim that Ipamorelin cannot affect GH. Gobburu had already modeled a GH response in volunteers. A solid-meal outcome and a GH curve do not cancel each other; they answer different questions.^3,2

NCT01280344

In the sources reviewed as of September 1, 2026, we did not identify published efficacy numbers for NCT01280344. This page does not invent rates, times, or differences. A Completed registry documents that the study closed; it does not replace a paper.⁵

This record is also not treated as a positive or negative replication of Beck 2014. Without posted results there is no replication to cite. The title again places the question in gastrointestinal function, not in the GH axis as an efficacy endpoint and not in combination with CJC-1295.^5,3

Two Phase 2 registries — one published as Beck 2014 and one without results — describe a motility program, not a body-composition program and not a blend program.

FDA review

The advisory committee voted on those nominations. FDA had proposed against inclusion on the 503A list. The votes are advisory recommendations. They are not an approval and not a drug ban.⁷

The compounding-risks page, reviewed on 1 September 2026, places ipamorelin acetate in Category 2 under the 503B interim policy and also among withdrawn nominations. The safety language includes immunogenicity, aggregation and impurities, and unnatural amino acids.⁸

That entry also references serious adverse events, including death, in the intravenous gastric-motility clinical-development context. FDA does not establish causality in that sentence. This page does not write “Ipamorelin caused deaths.” It also does not generalize those intravenous data to every route.⁸

Summarizing the Agency’s concern is not a use instruction. No technique, reconstitution step, or quantity is offered. The scope is compounding and clinical development as FDA described them, not a safety card for a commercial research vial.

GH versus gastrointestinal

Ipamorelin was studied as a GH secretagogue and, later, as a candidate in postoperative ileus. Those lines cannot be merged. A volunteer GH PK/PD model does not predict time to a solid meal. A non-significant gastrointestinal endpoint does not erase GH pharmacology.

FDA evaluated nominations for both GHD and ileus. That dual administrative mention does not turn Beck into a GHD trial or Gobburu into an ileus trial. Each source stays with its question.^6,3,2

A GH increase, again, is not muscle, fat, recovery, anti-aging, sleep, or performance. The Gobburu paper is not cited for those readings.²

What it does not establish

• It does not establish clinical efficacy on the published gastrointestinal endpoint.³
• It does not establish efficacy numbers for NCT01280344: the registry is Completed and posts no results.⁵
• It does not establish that Ipamorelin has no adverse effects, or that it does not affect cortisol in people. Raun 1998 is preclinical.¹
• It does not establish that intravenous motility adverse events apply to every route, or that Ipamorelin “caused deaths.”⁸
• It does not establish CJC-1295 + Ipamorelin evidence. Component evidence is not combination evidence.^2,3
• It does not establish muscle, fat, sleep, recovery, anti-aging, or performance from a GH response.²

In the sources reviewed as of September 1, 2026, we did not identify a human trial that administered Ipamorelin together with CJC-1295, nor posted results for NCT01280344, nor a human trial that turned Raun’s preclinical selectivity into an unconditional safety claim.^5,1

If the question is whether the exact pair has evidence of its own, combination evidence. If the question is why two pathways are discussed together, GHRH, ghrelin, and two signaling pathways. The index is the cluster hub.